Physician profile
Jonathan Nava
NPI 1760828784
$3,980.50
in general payments reported to CMS, 2019-2025
30 companies · $1,003 in 2025
The $1,003 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $380 · 2020: $129 · 2021: $187 · 2022: $429 · 2023: $1,122 · 2024: $729 · 2025: $1,003.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,855.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,855.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $605.86 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $459.05 | 2019-2024 | Xarelto |
| Pfizer INC. | $413.26 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $223.37 | 2019-2025 | |
| Amgen INC. | $217.06 | 2019-2024 | Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $205.03 | 2023-2024 | Jardiance |
| Stryker Corporation | $203.52 | 2025 | Flowtriever |
| E.R. Squibb & Sons, L.L.C. | $194.83 | 2022-2025 | Camzyos, Eliquis |
| Astrazeneca Pharmaceuticals Lp | $152.99 | 2022-2025 | Andexxa, Lokelma |
| Abbott Laboratories | $133.28 | 2024 | Cardiomems |
| Viatris Specialty LLC | $124.32 | 2025 | Yupelri |
| Novo Nordisk INC | $123.03 | 2025 | Ozempic |
| Merck Sharp & Dohme LLC | $106.29 | 2019-2025 | Verquvo, Recarbrio, Zerbaxa |
| Gilead Sciences, INC. | $102.64 | 2022-2023 | Veklury |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $99.53 | 2024-2025 | Lifevest |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $87.60 | 2019-2024 | Yupelri |
| Chiesi USA, INC. | $85.13 | 2019-2024 | Cleviprex |
| Alexion Pharmaceuticals, INC. | $82.96 | 2023-2025 | Ultomiris, Soliris |
| Astellas Pharma US INC | $46.94 | 2019 | |
| Smith+Nephew, INC. | $46.01 | 2023-2025 | Collagenase Santyl |
| Bayer Healthcare Pharmaceuticals INC. | $45.81 | 2022-2025 | |
| Shionogi INC | $45.67 | 2023-2024 | Fetroja |
| Vifor Pharma, INC. | $36.03 | 2019-2020 | |
| Cvrx, INC. | $31.74 | 2025 | Barostim Neo System |
| Abiomed | $24.41 | 2024 | Impella |
| Vertex Pharmaceuticals Incorporated | $20.05 | 2025 | |
| Global Blood Therapeutics, INC. | $17.81 | 2021 | |
| Lilly USA, LLC | $16.30 | 2020 | |
| Melinta Therapeutics, LLC | $15.15 | 2025 | Rezzayo |
| Portola Pharmaceuticals, LLC | $14.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Nava listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.